Jupiter Topco LLC Acquires New Position in Enanta Pharmaceuticals, Inc. $ENTA

Jupiter Topco LLC acquired a new position in shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) during the 2nd quarter, HoldingsChannel reports. The firm acquired 3,654,920 shares of the biotechnology company’s stock, valued at approximately $53,252,000. Jupiter Topco LLC owned about 0.13% of Enanta Pharmaceuticals at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of ENTA. Meeder Asset Management Inc. acquired a new position in Enanta Pharmaceuticals in the fourth quarter valued at approximately $32,000. Seven Fleet Capital Management LP bought a new position in shares of Enanta Pharmaceuticals during the fourth quarter valued at approximately $36,000. Legal & General Group Plc acquired a new stake in shares of Enanta Pharmaceuticals during the 2nd quarter worth approximately $41,000. Strs Ohio acquired a new stake in shares of Enanta Pharmaceuticals during the 4th quarter worth approximately $50,000. Finally, Clearstead Trust LLC bought a new stake in shares of Enanta Pharmaceuticals in the 2nd quarter worth approximately $74,000. Institutional investors own 94.99% of the company’s stock.

Enanta Pharmaceuticals Trading Down 2.5%

Shares of NASDAQ:ENTA opened at $13.80 on Friday. The firm’s 50 day moving average is $13.57 and its two-hundred day moving average is $13.48. Enanta Pharmaceuticals, Inc. has a 52 week low of $7.05 and a 52 week high of $17.15. The firm has a market capitalization of $401.86 million, a P/E ratio of -5.73 and a beta of 0.98.

Enanta Pharmaceuticals (NASDAQ:ENTA) last released its quarterly earnings results on Monday, August 10th. The biotechnology company reported ($0.67) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.16). The business had revenue of $14.36 million for the quarter, compared to the consensus estimate of $16.76 million. Enanta Pharmaceuticals had a negative net margin of 96.89% and a negative return on equity of 61.84%. Analysts predict that Enanta Pharmaceuticals, Inc. will post -2.36 EPS for the current year.

Analyst Ratings Changes

A number of research analysts recently issued reports on ENTA shares. Wall Street Zen lowered Enanta Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, August 22nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Enanta Pharmaceuticals in a research report on Friday, July 17th. Finally, HC Wainwright reiterated a “buy” rating and issued a $20.00 target price on shares of Enanta Pharmaceuticals in a research note on Tuesday, June 23rd. Six research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $19.50.

Enanta Pharmaceuticals Profile

Enanta Pharmaceuticals, Inc is a biotechnology company headquartered in Watertown, Massachusetts, specializing in the discovery and development of novel, small-molecule drugs targeting viral diseases. Leveraging a proprietary chemistry platform, Enanta has built extensive expertise in designing potent inhibitors of viral proteases and polymerases. The company initially gained recognition through partnerships focused on hepatitis C virus (HCV), where its protease inhibitors formed a key component of ABBVIE’s direct‐acting antiviral regimens.

Building on its HCV experience, Enanta has expanded its pipeline to address respiratory syncytial virus (RSV) and other viral infections.